Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported second-quarter financial results and provided a detailed business update, emphasizing progress toward a 2027 Biologics License ...

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today provided an update on recent and anticipated ...

Obinutuzumab, a B-cell depleting therapy, is being explored for reducing lupus nephritis risks, such as flare.

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Identifying early predictors of chronic kidney disease (CKD) progression in patients with lupus nephritis may help define a high-risk group.

The most widely used classification criteria for both adult-onset SLE (aSLE) and cSLE are the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria and the 2019 European League ...

Using triple therapy with belimumab for initial lupus nephritis treatment was associated with early renal response in a study of real-world patients.

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

BARCELONA -- A small-molecule oral drug shaping up as a first-in-class to treat various forms of lupus performed well in a phase II trial, despite -- or perhaps even because of -- missing its ...